• Halozyme CEO Helen Torley exercised stock options, acquiring 50,000 common shares at $12.07 from June 1-3, 2026.
• Torley sold 50,000 common shares over the same period at weighted average prices of $66.31-$69.69.
• Directly owned common shares fell to 767,780 following the transactions.
• Options beneficially owned dropped to 1,923.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000074), on June 03, 2026, and is solely responsible for the information contained therein.